Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F15%3A10312429" target="_blank" >RIV/00216208:11140/15:10312429 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1586/14737159.2015.1110021" target="_blank" >http://dx.doi.org/10.1586/14737159.2015.1110021</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1586/14737159.2015.1110021" target="_blank" >10.1586/14737159.2015.1110021</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?

Popis výsledku v původním jazyce

The optimal choice of cancer therapy depends upon analysis of the rumor genome for druggable molecular alterations. The spatial and temporal intratumor heterogeneity of cencers creates substanital challenges, as molecular profile depends on time and siteof tumor tissue collection. To capture the entire molecular profile, multiple biopsies from primary and metastatic sites st different time points would be required, which is not feasible for ethical or economic reasons. Molecular analysis of circulatingcell-free DNA offers a novel, minimally invasive method that can be performaed at multiple time-points and plausibly better represents the prevailing molucular profile of the cancer. Molecular analysis of this cell-free DNA offers multiple clinically useful applications, such as identification of molecular targets for cancer therapy, monitoring of tumor molecular progile in real time, detection of emerging molecular aberrations associated with resistence to particular therapy, determina

Název v anglickém jazyce

Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?

Popis výsledku anglicky

The optimal choice of cancer therapy depends upon analysis of the rumor genome for druggable molecular alterations. The spatial and temporal intratumor heterogeneity of cencers creates substanital challenges, as molecular profile depends on time and siteof tumor tissue collection. To capture the entire molecular profile, multiple biopsies from primary and metastatic sites st different time points would be required, which is not feasible for ethical or economic reasons. Molecular analysis of circulatingcell-free DNA offers a novel, minimally invasive method that can be performaed at multiple time-points and plausibly better represents the prevailing molucular profile of the cancer. Molecular analysis of this cell-free DNA offers multiple clinically useful applications, such as identification of molecular targets for cancer therapy, monitoring of tumor molecular progile in real time, detection of emerging molecular aberrations associated with resistence to particular therapy, determina

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Review of Molecular Diagnostics

ISSN

1473-7159

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

14

Strana od-do

1631-1644

Kód UT WoS článku

000366202200001

EID výsledku v databázi Scopus

2-s2.0-84949535312